568 related articles for article (PubMed ID: 29786131)
1. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
2. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
4. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
5. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
7. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
[TBL] [Abstract][Full Text] [Related]
8. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma.
Chen T; Zhang MG; Xu HX; Wang WQ; Liu L; Yu XJ
Medicine (Baltimore); 2015 May; 94(19):e751. PubMed ID: 25984661
[TBL] [Abstract][Full Text] [Related]
10. Predictive Early Recurrence Factors of Preoperative Clinicophysiological Findings in Pancreatic Cancer.
Suzuki S; Shimoda M; Shimazaki J; Maruyama T; Oshiro Y; Nishida K; Sahara Y; Nagakawa Y; Tsuchida A
Eur Surg Res; 2018; 59(5-6):329-338. PubMed ID: 30453288
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of Serum CA19-9 in Patients Undergoing Pancreatic Cancer Resection.
van Oosten AF; Groot VP; Dorland G; Burkhart RA; Wolfgang CL; van Santvoort HC; He J; Molenaar IQ; Daamen LA
Ann Surg; 2024 Mar; 279(3):493-500. PubMed ID: 37389896
[TBL] [Abstract][Full Text] [Related]
12. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
13. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
14. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.
Motoi F; Murakami Y; Okada KI; Matsumoto I; Uemura K; Satoi S; Sho M; Honda G; Fukumoto T; Yanagimoto H; Kinoshita S; Kurata M; Aoki S; Mizuma M; Yamaue H; Unno M;
World J Surg; 2019 Feb; 43(2):634-641. PubMed ID: 30298281
[TBL] [Abstract][Full Text] [Related]
15. New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma.
Amburn T; Davenport D; Patel R; Moss J; Pandalai P; Kim J; Cavnar M
Am Surg; 2023 Nov; 89(11):4469-4478. PubMed ID: 35921431
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection.
Li J; Li Z; Kan H; Sun Z; Xing J; Cheng Y; Bai C
Pancreatology; 2019 Mar; 19(2):302-306. PubMed ID: 30737189
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
[TBL] [Abstract][Full Text] [Related]
19. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
